LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the return of its #Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer Awareness Month. First launched in 2021, the campaign supports DermTech’s core mission to help end deaths from melanoma, one of the deadliest forms of skin cancer, through early and reliable detection.
The #Stickit2Melanoma campaign officially began on May 2, 2022, known as Melanoma Monday. For every #Stickit2Melanoma pledge to schedule a skin exam, DermTech will make a $5 donation to its non-profit partner organizations focused on skin health. The campaign will support events, educational content and programs throughout the month of May. Last year, DermTech donated $250,000 and pledged up to $1 million over the next four years.
“Improving access to early, reliable melanoma detection is at the heart of our mission,” said John Dobak, M.D., CEO of DermTech. “We know the most effective way to help eliminate melanoma deaths is to identify the disease early. Through the #Stickit2Melanoma campaign, we are inspiring people to unite during Melanoma Awareness Month and take the skin exam pledge. Melanoma doesn’t discriminate, and by understanding the risks and how to take proper precautions, we can save lives.”
Popular influencers who have experience with melanoma are partnering with DermTech for the #Stickit2Melanoma campaign. They are helping to bring heightened awareness to melanoma and the importance of skin checks.
According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, melanoma is among the most common cancer types in the U.S. Early detection and treatment are especially critical in beating melanoma. If the cancer is localized, the five-year survival rate is 99.4%. This drops to 29.8% if the cancer spreads to distant parts of the body.
To join #Stickit2Melanoma and find a specialist to schedule a skin exam, visit www.dermtech.com/pledge.
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, benefits to research partners and collaborators, cost-effectiveness, commercialization and adoption of DermTech’s products and services and the market opportunity therefor, and DermTech’s ability to expand its product and service offerings. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products and services; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.